Adagrasib,Cetuximab,Afatinib,Pembrolizumab
Mirati,Eli Lilly,Boehringer Ingelheim,Merck
['rectal', 'colorectal', 'mirati']
join us for our poster presentation at #esmo22, where we re excited to present our late-breaking data in patients with advanced #colorectalcancer harboring the #krasg12c mutation. 
Our mission is to discover, design & deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. https://t.co/nXoCkyY6VT